The impact of intestinal microflora on the effectiveness of immunotherapy with antibodies against immune checkpoints — case report and literature review
暂无分享,去创建一个
[1] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[2] D. Pardoll,et al. The intestinal microbiome influences checkpoint blockade , 2018, Nature Medicine.
[3] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[4] E. Le Chatelier,et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.
[5] Riyue Bao,et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.
[6] S. Batra,et al. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. , 2017, Seminars in cancer biology.
[7] A. Szabo,et al. P1.07-008 Microbiome & Immunotherapy: Antibiotic Use Is Associated with Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors , 2017 .
[8] R. Boidot,et al. Antibiotic Use Does Not Appear to Influence Response to Nivolumab. , 2017, Anticancer research.
[9] L. Zitvogel,et al. Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2017 .
[10] D. Schadendorf,et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[12] Lieping Chen,et al. PD-1 as an immune modulatory receptor. , 2014, Cancer journal.
[13] R. Ley,et al. Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine , 2006, Cell.